LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial launch of fast-acting nasal spray treatment for erectile dysfunction, SPONTAN. Watch the video.
In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the funds would be allocated to fast-track commercialisation of its fast-acting nasal spray treatment for erectile dysfunction (ED), SPONTAN. “We’re scaling up our commercial manufacturing, and
LTR Pharma’s A$10.5 million share placement has been featured in The Australian Business Review. Click to read the article.
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711